| Item Type | Name |
|
Concept
|
Primary Myelofibrosis
|
|
Academic Article
|
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.
|
|
Academic Article
|
Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.
|
|
Academic Article
|
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
|
|
Academic Article
|
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
|
|
Academic Article
|
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
|
|
Academic Article
|
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
|
|
Academic Article
|
Clinical significance of microcytosis in patients with primary myelofibrosis.
|
|
Academic Article
|
Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis.
|
|
Academic Article
|
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
|
Academic Article
|
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
|
|
Academic Article
|
Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome.
|
|
Academic Article
|
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis.
|
|
Academic Article
|
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis
|
|
Academic Article
|
Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome
|
|
Academic Article
|
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
|
|
Academic Article
|
Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.
|
|
Academic Article
|
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
|
|
Academic Article
|
Therapy-related myelofibrosis does not appear to exist.
|
|
Academic Article
|
Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
|
|
Academic Article
|
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
|
|
Academic Article
|
Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis.
|
|
Academic Article
|
Myelofibrosis osteoclasts are clonal and functionally impaired.
|
|
Academic Article
|
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
|
|
Academic Article
|
Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
|
|
Academic Article
|
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
|
|
Academic Article
|
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.
|
|
Academic Article
|
Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis.
|
|
Academic Article
|
Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy.
|
|
Academic Article
|
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.
|
|
Academic Article
|
Improved survival of patients with myelofibrosis in the last decade: Single-center experience.
|
|
Academic Article
|
GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes.
|
|
Academic Article
|
The role of therapy in the outcome of patients with myelofibrosis.
|
|
Academic Article
|
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
|
|
Academic Article
|
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
|
|
Academic Article
|
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
|